Navigation Links
Inhibikase Awarded $433,000 from The Michael J. Fox Foundation to Advance Development of Kinase Inhibitor Treatment for Parkinson's Disease
Date:3/9/2017

ATLANTA, March 9, 2017 /PRNewswire/ -- Inhibikase Therapeutics, a clinical-stage specialty pharmaceutical company developing kinase inhibitors to treat neurodegenerative diseases and infections in the brain, announced today that the company has received a $433,000 research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to help fund pre-IND studies of the company's novel c-Abl kinase inhibitors as a potential disease-modifying treatment for Parkinson's disease (PD).

"Recent scientific discoveries point to a role of c-Abl kinase in the progression of Parkinson's disease. In our ongoing pursuit of orally administered, brain-penetrant c-Abl inhibitors to treat major diseases in the brain, we have generated c-Abl kinase inhibitors that have demonstrated the ability to block neurodegeneration in preclinical models of the disease," said Milton Werner, PhD, Chief Executive Officer of Inhibikase. "We are grateful to The Michael J. Fox Foundation for its support as we continue our work to validate this potential disease-modifying therapy that may impede the progression of Parkinson's disease."

Using its proprietary RAMP technology engine, Inhibikase has discovered and developed a series of c-Abl kinase inhibitors and validated their activity in preclinical animal models for multiple therapeutic indications in the brain. Building on newly discovered mechanistic data, the company evaluated its RAMP molecules in preclinical animal models of PD, demonstrating that these molecules are capable of blocking the progressive death of dopamine-producing neurons that drives PD and thus acting as a potential disease-modifying therapy for PD. 

The grant will support studies of the activity and pharmacology of the RAMP molecules in a newly defined mouse model that recapitulates many of the hallmarks of the progressive disease process in humans. RAMP molecules that pass these tests will be positioned to advance through the regulatory requirements to begin clinical testing. 

This work supplements two-FDA approved clinical studies under way by Inhibikase that are evaluating commercial anti-cancer c-Abl inhibitors as potential bridging therapies in PD until the company's RAMP molecules reach clinical testing in humans.

About Inhibikase Therapeutics (www.inhibikase.com)
Inhibikase Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company innovating small-molecule therapeutics that target central nervous system (CNS) diseases, including neurodegenerative diseases and life-threatening brain infections. Founded in 2008 and headquartered in Atlanta, with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is transforming the pathway to blunt and reverse diseases in the brain and CNS.

About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, advocacy volunteers and donors. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit www.michaeljfox.org.

Contact:

Mary Moynihan
M2Friend Biocommunications
mary@m2friend.com
(802) 951-9600

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inhibikase-awarded-433000-from-the-michael-j-fox-foundation-to-advance-development-of-kinase-inhibitor-treatment-for-parkinsons-disease-300420967.html


'/>"/>
SOURCE Inhibikase
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Inhibikase Therapeutics, Inc. lance une étude clinique pour ceux qui ont survécu à la LEMP
2. Inhibikase Therapeutics, Inc., startet klinische Studie für PML-Überlebende
3. Inhibikase Therapeutics, Inc. Launches Clinical Study For Survivors Of PML
4. SRI International Awarded Two BARDA Contracts to Provide Nonclinical Research Services
5. Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the Treatment of Schizophrenia
6. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
7. Voxeleron Awarded NIH SBIR Grant for Device-independent Retinal Image Analysis Software Platform
8. IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s
9. NanoBio Awarded U.S. Patent for RSV Vaccine
10. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
11. Salk Institute awarded $25 million grant from Helmsley Charitable Trust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , June 28, 2017  Scientific Analytics, Inc.,s DARI ... showcased in front of thousands of healthcare providers at Premier ... 27.   Scientific Analytics, DARI Motion Health was debuted ... recognizes advances in healthcare while highlighting industry suppliers committed to ... ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... international market with three research projects accepted for presentation at the 33rd Annual ... Nearly 10,000 participants – including some of the world’s top thought leaders in ...
(Date:6/28/2017)... ... ... Studies indicate that replacing damaged brain cells with those derived from human ... has not been determined is the optimal stage during differentiation of the stem cells ... study coming out of Singapore, recently published in STEM CELLS Translational Medicine journal may ...
(Date:6/27/2017)... ... 2017 , ... According to a recent report from the ... have negative short- or long-term effects on benthic communities. , The ESTCP ... at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, Washing. ...
Breaking Biology Technology:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):